跳至主要内容
临床试验/NCT06836492
NCT06836492招募中3 期

A Prospective Clinical Cohort Study on Stratified Treatment of Rhabdomyosarcoma Based on Risk Factors: a Single Arm Trial.

Yizhuo Zhang1 个研究点 分布在 1 个国家目标入组 300 人开始时间: 2017年1月30日最近更新:
适应症

试验速览

阶段
3 期
状态
招募中
发起方
入组人数
300
试验地点
1
主要终点
The objective response rate (ORR)

研究概览

简要总结

The purpose is to explore the efficacy and safety of the SYSUCC-RMS regimen for pediatric RMS patients and to explore the impact of concurrent radiotherapy and chemotherapy on the survival rate of low-risk, medium risk, high-risk, and extremely high-risk patients in children.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
0 Years 至 18 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • 0 years < age < 18 years old, regardless of gender;
  • Tumor patients diagnosed by histopathology or bone marrow cytology;
  • Patients are treated for the first time;
  • ECoG score ≤ 2;
  • The expected survival time is more than 8 months;
  • Patient's parent or guardian signs informed consent.

排除标准

  • Combined with immunodeficiency disease
  • Second tumor

结局指标

主要结局

The objective response rate (ORR)

时间窗: Up to 1 year

The ORR was calculated based on the best overall response.

disease control rate (DCR)

时间窗: Up to 1 year

progression-free survival (PFS)

时间窗: Up to 10 years

Furthermore, we provided Kaplan-Meier plots for PFS

overall survival (OS)

时间窗: Up to 10 years

Furthermore, we provided Kaplan-Meier plots for OS.

次要结局

  • The safety of the SYSUCC-RMS regimen for pediatric RMS patients.(Up to 10 years)

研究者

发起方
Yizhuo Zhang
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Yizhuo Zhang

Sun Yat-sen University Cancer Center

Sun Yat-sen University

研究点 (1)

Loading locations...

相似试验